For older patients, Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief --two new studies

Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find Overall, the risk of developing 28 out of 36 long-COVID symptoms lessened when vaccines were effective. CIDRAP

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Benefit seen only in older patients